(E)-methyl 2-(2-(dimethylamino)vinyl)-5-nitrobenzoate | 1036388-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-methyl 2-(2-(dimethylamino)vinyl)-5-nitrobenzoate
• 英文别名: methyl (E)-2-(2-(dimethylamino)vinyl)-5-nitrobenzoate；methyl 2-[(E)-2-(dimethylamino)ethenyl]-5-nitrobenzoate
• CAS: 1036388-63-2
• 化学式: C₁₂H₁₄N₂O₄
• 分子量: 250.254
• InChiKey: HQHFAXQNQDZMFK-VOTSOKGWSA-N

物化性质

• 沸点：
  379.2±37.0 °C(Predicted)
• 密度：
  1.227±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-methyl 2-(2-(dimethylamino)vinyl)-5-nitrobenzoate 在 N-溴代丁二酰亚胺(NBS) 、 三氟乙酸 作用下， 以 N,N-二甲基乙酰胺 、 甲苯 为溶剂， 反应 6.17h， 生成 4-bromo-7-nitroisoquinolin-1(2H)-one
  参考文献：
  名称：

  Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

  摘要：

  Inhibitors of Factor Vila (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the Si binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the Si pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this PI binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

  DOI：

  10.1021/acsmedchemlett.6b00282
• 作为产物：
  描述：

  2-甲基-5-硝基苯甲酰氯 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 (E)-methyl 2-(2-(dimethylamino)vinyl)-5-nitrobenzoate
  参考文献：
  名称：

  Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

  摘要：

  Inhibitors of Factor Vila (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the Si binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the Si pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this PI binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

  DOI：

  10.1021/acsmedchemlett.6b00282

文献信息

• [EN] 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS<br/>[FR] COMPOSÉS 1-OXO-1,2-DIHYDROISOQUINOLÉINE-7-YL-(5-SUBSTITUÉ-THIOPHÉN-2-YL)-SULFONAMIDE, FORMULATIONS CONTENANT CES COMPOSÉS ET LEUR UTILISATION COMME INHIBITEURS D'AICARFT DANS LE TRAITEMENT DE CANCERS
  申请人：LILLY CO ELI

  公开号：WO2016089670A1

  公开（公告）日：2016-06-09

  1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.

  1-Oxo-1,2-二氢异喹啉-7-基-(5-取代噻吩-2-基)-磺酰胺化合物，含有这些化合物的配方，以及它们作为AICARFT抑制剂的用途。
• [EN] SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE MPGES-1
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2014167444A1

  公开（公告）日：2014-10-16

  The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

  本公开涉及式(I)的化合物及其药学上可接受的盐，作为mPGES-1抑制剂。这些化合物是微粒体前列腺素E合成酶-1（mPGES-1）酶的抑制剂，因此在治疗多种疾病或病况引起的疼痛和/或炎症方面具有用处，如哮喘、骨关节炎、类风湿性关节炎、急性或慢性疼痛和神经退行性疾病。
• BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
  申请人：Wurtz Nicholas Ronald

  公开号：US20100041664A1

  公开（公告）日：2010-02-18

  The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z 1 , Z 2 , Z 3 , Z 4 , R 8 , and R 9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

  本发明提供了新型双环内酰胺衍生物及其类似物，其化学式为(I)：或其立体异构体、互变异构体、药学上可接受的盐、溶剂化物或前药。其中，变量A、B、C、W、Y、Z1、Z2、Z3、Z4、R8和R9的定义如本文所述。这些化合物是选择性因子VIIa抑制剂，可用作药物。
• [EN] DIARYLHYDANTOIN DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF<br/>[FR] DÉRIVÉ DE DIARYLHYDANTOÏNE ET PROCÉDÉ DE PRÉPARATION, COMPOSITION PHARMACEUTIQUE ET UTILISATION CORRESPONDANTS
  申请人：SHANGHAI PHARMACEUTICALS HOLDING CO LTD

  公开号：WO2015018356A1

  公开（公告）日：2015-02-12

  本发明公开了二芳基乙内酰脲衍生物、其制备方法、药物组合物和应用。本发明提供了一种如式I所示的二芳基乙内酰脲衍生物、其药学上可接受的盐、溶剂化物、代谢产物、立体异构体、互变异构体、多晶型物或其药物前体，本发明的二芳基乙内酰脲衍生物对于治疗雄激素受体相关疾病，特别是去势耐受型前列腺癌有着良好的效果。
• [EN] MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS<br/>[FR] INHIBITEURS MACROCYCLIQUES DU FACTEUR VIIA UTILES EN TANT QU'ANTICOAGULANTS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2008079836A4

  公开（公告）日：2009-03-12